atenolol and Aneurysm, Aortic studies

Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.
atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.

Research Excerpts

Excerpt	Relevance	Reference
"Long-term outcome of Marfan syndrome patients randomly assigned to losartan or atenolol showed no differences in aortic dilation rate or presence of clinical events between treatment groups."	9.27	Losartan Versus Atenolol for Prevention of Aortic Dilation in Patients With Marfan Syndrome. ( Evangelista, A; Forteza, A; García-Dorado, D; González Mirelis, J; Gutiérrez, L; Ibáñez, B; Rodríguez-Palomares, J; Sánchez, V; Teixido-Tura, G, 2018)
" atenolol in aortic dilation progression in Marfan syndrome (MFS) patients."	9.22	Efficacy of losartan vs. atenolol for the prevention of aortic dilation in Marfan syndrome: a randomized clinical trial. ( Centeno, J; Cortina, J; Evangelista, A; Ferreira-González, I; Forteza, A; García-Dorado, D; Gracia, T; Gutiérrez, L; Rodríguez-Palomares, J; Rufilanchas, JJ; Sánchez, V; Sanz, P; Teixidó-Turà, G, 2016)
"We conducted a randomized, double-blind trial of losartan (100 mg QD) versus atenolol (50 mg QD) for 6 months in adults with Marfan syndrome."	9.20	Distinct effects of losartan and atenolol on vascular stiffness in Marfan syndrome. ( Bhatt, AB; Buck, JS; Creager, MA; Gauvreau, K; Kadivar, S; Milian, J; Singh, MN; Zuflacht, JP, 2015)
"Long-term outcome of Marfan syndrome patients randomly assigned to losartan or atenolol showed no differences in aortic dilation rate or presence of clinical events between treatment groups."	5.27	Losartan Versus Atenolol for Prevention of Aortic Dilation in Patients With Marfan Syndrome. ( Evangelista, A; Forteza, A; García-Dorado, D; González Mirelis, J; Gutiérrez, L; Ibáñez, B; Rodríguez-Palomares, J; Sánchez, V; Teixido-Tura, G, 2018)
" atenolol in aortic dilation progression in Marfan syndrome (MFS) patients."	5.22	Efficacy of losartan vs. atenolol for the prevention of aortic dilation in Marfan syndrome: a randomized clinical trial. ( Centeno, J; Cortina, J; Evangelista, A; Ferreira-González, I; Forteza, A; García-Dorado, D; Gracia, T; Gutiérrez, L; Rodríguez-Palomares, J; Rufilanchas, JJ; Sánchez, V; Sanz, P; Teixidó-Turà, G, 2016)
"We conducted a randomized, double-blind trial of losartan (100 mg QD) versus atenolol (50 mg QD) for 6 months in adults with Marfan syndrome."	5.20	Distinct effects of losartan and atenolol on vascular stiffness in Marfan syndrome. ( Bhatt, AB; Buck, JS; Creager, MA; Gauvreau, K; Kadivar, S; Milian, J; Singh, MN; Zuflacht, JP, 2015)
" One of the twins suffered a type A aortic dissection, which required replacement of the ascending aorta, and the other twin had an aneurysmal dilatation of the ascending aorta (46mm) and was prescribed medical treatment with atenolol and periodic controls to detect the presence of a critical diameter (50mm) that would indicate the need for prophylactic surgery."	3.74	Monozygotic twins with Marfan's syndrome and ascending aortic aneurysm. ( Belforte, SM; Cianciulli, TF; Lax, JA; Picone, VP; Prezioso, HA; Recalde, B; Redruello, HJ; Rostello, EF, 2007)

Research

Studies (16)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Annual Rate of Change in Aortic Root (Sinuses of Valsalva) Absolute Dimension

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (6.25)	18.7374
1990's	1 (6.25)	18.2507
2000's	3 (18.75)	29.6817
2010's	11 (68.75)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Teixido-Tura, G	2
Forteza, A	2
Rodríguez-Palomares, J	2
González Mirelis, J	1
Gutiérrez, L	2
Sánchez, V	2
Ibáñez, B	1
García-Dorado, D	2
Evangelista, A	2
Bowen, JM	1
Connolly, HM	1
Lacro, RV	2
Dietz, HC	2
Sleeper, LA	1
Yetman, AT	1
Bradley, TJ	1
Colan, SD	1
Pearson, GD	1
Selamet Tierney, ES	1
Levine, JC	1
Atz, AM	1
Benson, DW	1
Braverman, AC	1
Chen, S	1
De Backer, J	1
Gelb, BD	1
Grossfeld, PD	1
Klein, GL	1
Lai, WW	1
Liou, A	1
Loeys, BL	1
Markham, LW	1
Olson, AK	1
Paridon, SM	1
Pemberton, VL	1
Pierpont, ME	1
Pyeritz, RE	1
Radojewski, E	1
Roman, MJ	1
Sharkey, AM	1
Stylianou, MP	1
Wechsler, SB	1
Young, LT	1
Mahony, L	2
Treasure, T	1
Pepper, J	1
Mohiaddin, R	1
Ziganshin, BA	1
Mukherjee, SK	1
Elefteriades, JA	1
Mallat, Z	1
Tedgui, A	1
Bhatt, AB	1
Buck, JS	1
Zuflacht, JP	1
Milian, J	1
Kadivar, S	1
Gauvreau, K	1
Singh, MN	1
Creager, MA	1
Lengellé, C	1
Bejan-Angoulvant, T	1
Beau-Salinas, F	1
Jonville-Béra, AP	1
Sanz, P	1
Gracia, T	1
Centeno, J	1
Rufilanchas, JJ	1
Cortina, J	1
Ferreira-González, I	1
O'Rourke, MF	1
Adji, A	1
Weber, T	1
Chockalingam, A	1
Gnanavelu, G	1
Alagesan, R	1
Redruello, HJ	1
Cianciulli, TF	1
Rostello, EF	1
Recalde, B	1
Lax, JA	1
Picone, VP	1
Belforte, SM	1
Prezioso, HA	1
Jondeau, G	1
Barthelet, M	1
Baumann, C	1
Bonnet, D	1
Chevallier, B	1
Collignon, P	1
Dulac, Y	1
Edouard, T	1
Faivre, L	1
Germain, D	1
Khau Van Kien, P	1
Lacombe, D	1
Ladouceur, M	1
Lemerrer, M	1
Leheup, B	1
Lupoglazoff, JM	1
Magnier, S	1
Muti, C	1
Plauchu, PH	1
Raffestin, B	1
Sassolas, F	1
Schleich, JM	1
Sidi, D	1
Themar-Noël, C	1
Varin, J	1
Wolf, JE	1
Moursi, MM	1
Beebe, HG	1
Messina, LM	1
Welling, TH	1
Stanley, JC	1
Leach, SD	1
Toole, AL	1
Stern, H	1
DeNatale, RW	1
Tilson, MD	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Trial of Beta Blocker Therapy (Atenolol) Versus Angiotensin II Receptor Blocker Therapy (Losartan) in Individuals With Marfan Syndrome (A Trial Conducted by the Pediatric Heart Network)[NCT00429364]	Phase 3	608 participants (Actual)	Interventional	2007-01-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

The rate of change in the absolute dimension of the aortic root over a 3-year period following randomization (NCT00429364)
Timeframe: Up to 3 years following randomization.

Annual Rate of Change in Aortic Root (Sinuses of Valsalva) Body-surface-area-adjusted Z-score

Intervention	cm/year (Least Squares Mean)
Atenolol	0.069
Losartan	0.075

The rate of aortic root enlargement, expressed as the annual change in the maximum aortic-root-diameter z score indexed to body-surface area over a 3-year period following randomization (NCT00429364)
Timeframe: Up to 3 years following randomization.

Annual Rate of Change in Aortic-annulus-diameter Z Score, Adjusted by Body-surface Area

Annual Rate of Change in Arm Span to Height Ratio

Annual Rate of Change in Ascending-aorta-diameter Z Score, Adjusted by Body-surface-area.

Annual Rate of Change in Body Mass Index

Annual Rate of Change in Body Mass Index for Age Z-score

Annual Rate of Change in Height

Annual Rate of Change in Height-for-age Z-score

Annual Rate of Change in the Absolute Diameter of the Aortic Annulus

Annual Rate of Change in the Absolute Diameter of the Ascending Aorta

Annual Rate of Change in Total Aortic Proximal Regurgitant Jet Area Indexed to Body-surface-area

Annual Rate of Change in Upper to Lower Segment Ratio

Annual Rate of Change in Weight

Annual Rate of Change in Weight-for-age Z-score

Annual Rate of Change in Weight-for-height Z-score

Event Rate of Aortic Dissection.

Intervention	z-score/year (Least Squares Mean)
Atenolol	-0.139
Losartan	-0.107

Intervention	z-score/year (Least Squares Mean)
Atenolol	-0.279
Losartan	-0.175

Intervention	1/year (Least Squares Mean)
Atenolol	0.001
Losartan	0.001

Intervention	z-score/year (Least Squares Mean)
Atenolol	-0.140
Losartan	-0.114

Intervention	kg/m^2 per year (Least Squares Mean)
Atenolol	0.063
Losartan	0.076

Intervention	z-score/year (Least Squares Mean)
Atenolol	0.007
Losartan	0.021

Intervention	cm/year (Least Squares Mean)
Atenolol	0.822
Losartan	0.935

Intervention	z-score/year (Least Squares Mean)
Atenolol	0.046
Losartan	0.019

Intervention	cm/year (Least Squares Mean)
Atenolol	0.015
Losartan	0.030

Intervention	cm/year (Least Squares Mean)
Atenolol	0.039
Losartan	0.044

Intervention	(mm^2/m^2)/year (Least Squares Mean)
Atenolol	0.005
Losartan	0.001

Intervention	1/year (Least Squares Mean)
Atenolol	-0.014
Losartan	-0.015

Intervention	kg/year (Least Squares Mean)
Atenolol	0.239
Losartan	0.229

Intervention	z-score/year (Least Squares Mean)
Atenolol	0.011
Losartan	0.019

Intervention	z-score/year (Least Squares Mean)
Atenolol	-0.001
Losartan	-0.157

Percentage of participants who had aortic dissection over a 3-year period following randomization. (NCT00429364)
Timeframe: Up to 3 years following randomization.

Event Rate of Aortic-Root Surgery

Intervention	Percentage of participants (Number)
Atenolol	0
Losartan	0.7

Percentage of participants who had aortic-root surgery over a 3-year period following randomization. (NCT00429364)
Timeframe: Up to 3 years following randomization.

Event Rate of Death

Intervention	Percentage of participants (Number)
Atenolol	3.4
Losartan	6.0

Percentage of participants who died over a 3-year period following randomization. (NCT00429364)
Timeframe: Up to 3 years following randomization.

Event Rate of the Composite Adverse Clinical Outcomes, Including Aortic Dissection, Aortic-root Surgery and Death.

Intervention	Percentage of participants (Number)
Atenolol	0
Losartan	0.3

Percentage of participants who had aortic dissection, aortic-root surgery or death over a 3-year period following randomization (NCT00429364)
Timeframe: Up to 3 years following randomization.

Intervention	participants (Number)
	Headache, any severity	Headache, bothersome	Fatigue, any severity	Fatigue, bothersome	Mood alterations, any severity	Mood alterations, bothersome	Behavior changes, any severity	Behavior changes, bothersome	Insomnia, any severity	Insomnia, bothersome	Nightmares, any severity	Nightmares, bothersome	Dizziness with standing, any severity	Dizziness with standing, bothersome	Dizziness - other, any severity	Dizziness - other, bothersome	Fainting with loss of consciousness, any severity	Fainting with loss of consciousness, bothersome	Palpitations, any severity	Palpitations, bothersome	Chest pain, any severity	Chest pain, bothersome	Dyspnea, any severity	Dyspnea, bothersome	Wheezing, any severity	Wheezing, bothersome	Upper respiratory/Nasal congestion, any severity	Upper respiratory/Nasal congestion, bothersome	Cough, any severity	Cough, bothersome	Dysgeusia, any severity	Dysgeusia, bothersome	Stomach pain/Indigestion, any severity	Stomach pain/Indigestion, bothersome	Nausea, any severity	Nausea, bothersome	Vomiting, any severity	Vomiting, bothersome	Diarrhea, any severity	Diarrhea, bothersome	Constipation, any severity	Constipation, bothersome	Vascular (hands, feet), any severity	Vascular (hands, feet), bothersome	Muscle pain or Cramps, any severity	Muscle pain or Cramps, bothersome	Back pain, any severity	Back pain, bothersome	Periorbital edema, any severity	Periorbital edema, bothersome	Pedal edema, any severity	Pedal edema, bothersome	Other, any severity	Other, bothersome
Atenolol	112	10	84	0	54	7	21	2	60	2	52	2	60	0	25	0	5	5	60	0	54	1	43	3	15	2	106	0	47	1	10	0	47	0	30	1	23	0	35	1	44	0	35	0	59	2	60	3	13	0	2	0	21	3
Losartan	114	10	105	0	49	3	23	1	61	2	53	3	58	2	27	1	9	9	53	0	58	5	38	0	14	1	117	2	59	0	3	0	61	1	35	0	23	0	43	1	35	0	34	1	58	4	67	2	15	0	3	0	16	1

Intervention	participants (Number)
	Headache, any severity	Headache, bothersome	Fatigue, any severity	Fatigue, bothersome	Mood alterations, any severity	Mood alterations, bothersome	Behavior changes, any severity	Behavior changes, bothersome	Insomnia, any severity	Insomnia, bothersome	Nightmares, any severity	Nightmares, bothersome	Dizziness with standing, any severity	Dizziness with standing, bothersome	Dizziness - other, any severity	Dizziness - other, bothersome	Fainting with loss of consciousness, any severity	Fainting with loss of consciousness, bothersome	Palpitations, any severity	Palpitations, bothersome	Chest pain, any severity	Chest pain, bothersome	Dyspnea, any severity	Dyspnea, bothersome	Wheezing, any severity	Wheezing, bothersome	Upper respiratory/Nasal congestion, any severity	Upper respiratory/Nasal congestion, bothersome	Cough, any severity	Cough, bothersome	Dysgeusia, any severity	Dysgeusia, bothersome	Stomach pain/Indigestion, any severity	Stomach pain/Indigestion, bothersome	Nausea, any severity	Nausea, bothersome	Vomiting, any severity	Vomiting, bothersome	Diarrhea, any severity	Diarrhea, bothersome	Constipation, any severity	Constipation, bothersome	Vascular (hands, feet), any severity	Vascular (hands, feet), bothersome	Muscle pain or Cramps, any severity	Muscle pain or Cramps, bothersome	Back pain, any severity	Back pain, bothersome	Periorbital edema, any severity	Periorbital edema, bothersome	Pedal edema, any severity	Pedal edema, bothersome	Other, any severity	Other, bothersome
Atenolol	202	27	152	7	89	13	51	5	108	6	100	7	119	6	60	2	21	21	86	0	114	14	75	1	36	2	188	3	117	1	29	0	119	2	99	0	81	1	94	1	77	1	73	0	148	6	137	5	22	0	6	0	105	10
Losartan	208	20	153	5	86	13	46	8	107	4	94	4	105	0	61	0	16	16	101	0	106	1	72	3	32	5	186	3	113	1	16	0	121	8	78	0	75	2	90	3	66	0	66	0	124	7	134	8	27	1	5	0	108	12

Article	Year
Losartan Versus Atenolol for Prevention of Aortic Dilation in Patients With Marfan Syndrome. Journal of the American College of Cardiology, 2018, 10-02, Volume: 72, Issue:14 Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Angiotensin II Type 1 Receptor Blockers; Aorta; Aorti	2018
Atenolol versus losartan in children and young adults with Marfan's syndrome. The New England journal of medicine, 2014, Nov-27, Volume: 371, Issue:22 Topics: Adrenergic beta-Antagonists; Adult; Angiotensin II Type 1 Receptor Blockers; Aorta; Aortic Aneurysm;	2014
Distinct effects of losartan and atenolol on vascular stiffness in Marfan syndrome. Vascular medicine (London, England), 2015, Volume: 20, Issue:4 Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Angiotensin II Type 1 Receptor Blockers; Aortic Aneur	2015
Efficacy of losartan vs. atenolol for the prevention of aortic dilation in Marfan syndrome: a randomized clinical trial. European heart journal, 2016, Mar-21, Volume: 37, Issue:12 Topics: Adolescent; Adult; Angiotensin II Type 1 Receptor Blockers; Aorta; Aortic Aneurysm; Atenolol; Child;	2016

Article	Year
Of Marfan's syndrome, mice, and medications. The New England journal of medicine, 2014, Nov-27, Volume: 371, Issue:22 Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Aorta; Aortic Aneurysm; Atenol	2014
Atenolol versus Losartan in Marfan's Syndrome. The New England journal of medicine, 2015, 03-05, Volume: 372, Issue:10 Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Aorta; Aortic Aneurysm; Atenol	2015
Atenolol versus Losartan in Marfan's Syndrome. The New England journal of medicine, 2015, 03-05, Volume: 372, Issue:10 Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Aorta; Aortic Aneurysm; Atenol	2015
Atenolol versus Losartan in Marfan's Syndrome. The New England journal of medicine, 2015, 03-05, Volume: 372, Issue:10 Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Aorta; Aortic Aneurysm; Atenol	2015
Atenolol versus Losartan in Marfan's Syndrome. The New England journal of medicine, 2015, 03-05, Volume: 372, Issue:10 Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Aorta; Aortic Aneurysm; Atenol	2015
[Drugs news]. Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, 2015, Volume: 22, Issue:11 Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Anti-Obesity Agents; Anticonvu	2015
Correspondence regarding: Distinct effects of losartan and atenolol on vascular stiffness in Marfan syndrome by Bhatt et al. Vascular medicine (London, England), 2016, Volume: 21, Issue:1 Topics: Adrenergic beta-1 Receptor Antagonists; Angiotensin II Type 1 Receptor Blockers; Aortic Aneurysm; At	2016
Massive aortic aneurysm presenting as chest wall swelling. Heart (British Cardiac Society), 2004, Volume: 90, Issue:3 Topics: Aged; Anti-Arrhythmia Agents; Anti-Bacterial Agents; Aortic Aneurysm; Atenolol; Edema; Humans; Male;	2004
Monozygotic twins with Marfan's syndrome and ascending aortic aneurysm. European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology, 2007, Volume: 8, Issue:4 Topics: Adult; Aorta; Aortic Aneurysm; Aortic Dissection; Atenolol; Humans; Male; Marfan Syndrome; Twins, Mo	2007
[Recommendations for the medical management of aortic complications of Marfan's syndrome]. Archives des maladies du coeur et des vaisseaux, 2006, Volume: 99, Issue:5 Topics: Adrenergic beta-Antagonists; Aortic Aneurysm; Aortic Dissection; Atenolol; Bisoprolol; Calcium Chann	2006
Inhibition of aortic aneurysm development in blotchy mice by beta adrenergic blockade independent of altered lysyl oxidase activity. Journal of vascular surgery, 1995, Volume: 21, Issue:5 Topics: Animals; Aorta, Thoracic; Aortic Aneurysm; Atenolol; Blood Pressure; Heart Rate; Male; Mice; Mice, M	1995
Effect of beta-adrenergic blockade on the growth rate of abdominal aortic aneurysms. Archives of surgery (Chicago, Ill. : 1960), 1988, Volume: 123, Issue:5 Topics: Adrenergic beta-Antagonists; Aged; Aorta, Abdominal; Aortic Aneurysm; Atenolol; Female; Humans; Male	1988

atenolol and Aneurysm, Aortic